GoodRx Holdings

GoodRx Holdings, Inc. operates a consumer-focused digital healthcare platform. The firm offers information and tools to help consumers compare prices for prescription drugs. It operates applications and websites that provide prices and discounts at local and mail-order pharmacies. The company was founded by in Trevor Bezdek and Douglas Hirsch Joseph in September 2015 and is headquartered in Santa Monica, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GoodRx reports Q4 revenue decline but anticipates growth opportunities

GoodRx's Q4 2022 performance showed a decline in revenue but improvements in adjusted EBITDA. The company's focus on deepening relationships, increasing savings, and leveraging data presents strengths. Challenges include financial impacts from the grocer issue and decisions on revenue streams. Opportunities lie in non-grocery retailers, pharma manufacturer solutions, and sales optimization.

GoodRx reports strong Q1 performance and anticipates growth opportunities

GoodRx's Q1 performance reflects growth and positive outlook for managed solutions segment, despite challenges in revenue moderation and deal timelines.
The company's strengths lie in its strong foundation, talented team, and unique marketplace value proposition, with opportunities for further growth and innovation.
Challenges include potential revenue impact from program moderation and deal delays, but regulatory proposals are not expected to significantly affect business operations.
Overall, GoodRx remains focused on driving volume growth, maintaining market leadership, and providing affordable prescriptions to consumers.

GoodRx exceeds Q2 guidance, focuses on growth and partnerships

GoodRx's Q2 2023 earnings call showcased strong financial performance, exceeding guidance and reporting net income driven by a release of valuation allowance.
The company's focus on growth, profitability, and strategic realignment positions it well for compounding growth in 2024 and beyond, emphasizing proactive retail partnerships and efficient customer service strategies.
While challenges in deprioritizing certain solutions and balancing marketing spend efficiency exist, opportunities in optimizing retailer partnerships, leveraging data analytics, and attracting new members without incremental spend are key for future success.
Overall, GoodRx's innovative approach, unique value proposition, and financial and operational strengths highlight its resilience and potential for sustained growth and profitability.

GoodRx reports revenue growth and eyes pharma solutions expansion

GoodRx reported solid Q3 performance with revenue growth and strong cash generation, focusing on margin improvement and bottom-line profitability.
Despite challenges in subscription revenue and one-time payments, the company is eyeing growth opportunities in ISP, pharma solutions, and marketing efforts.
Analyst questions addressed key areas like retail stability, revenue growth expectations, and margin dynamics, indicating investor interest in future prospects.
GoodRx's strategic focus on expanding services, enhancing pricing strategies, and market access programs positions it for continued growth and value creation.

GoodRx exceeds Q4 expectations, eyes growth through strategic initiatives

GoodRx's Q4 '23 performance reflects strong financials, operational resilience, and strategic focus on growth initiatives.
The company's success in saving consumers billions and expanding market reach positions it well for future opportunities.
Challenges such as system issues and market competition require ongoing attention and strategic planning.
Opportunities in scaling solutions, targeted marketing, and strategic partnerships can drive sustained growth and market leadership.

GoodRx reports solid Q1 performance, eyes margin expansion opportunities

GoodRx's Q1 2024 performance showcased revenue growth and strong EBITDA margins, supported by strategic capital deployment and cash reserves.
Challenges include PTR per MAC decline and addressing analyst inquiries on ISP growth and margin concerns.
Opportunities lie in upcoming Analyst Day insights, ISP performance enhancements, and driving margin expansion through operational efficiencies.
Overall, GoodRx anticipates sustained growth, margin improvement, and continued ISP expansion throughout the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

NEW YORK , June 20, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of GoodRx Holdings, Inc. (NASDAQ: GDRX). Shareholders who purchased shares of GDRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

GoodRx Holdings, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before June 21, 2024 to Discuss Your Rights - GDRX

NEW YORK, NY / ACCESSWIRE / June 19, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=86411&wire=1 or contact Joseph E. Levi, Esq.

Contact Levi & Korsinsky by June 21, 2024 Deadline to Join Class Action Against GoodRx Holdings, Inc.(GDRX)

RADNOR, Pa., June 19, 2024 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against GoodRx Holdings, Inc. (NASDAQ: GDRX) (“GoodRx” or the “Company”) on behalf of investors who purchased or acquired GoodRx common stock between September 23, 2020, and November 8, 2022, inclusive (the “Class Period”). This action, captioned Barsuli v. GoodRx Holdings, Inc., et al., Case No. Case 2:24-cv-03282- DDP-AJR was filed in the United States District Court for the Central District of California.

Deadline in 2 Days: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against GoodRx Holdings, Inc. (GDRX)

NEW YORK, NY / ACCESSWIRE / June 19, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=86405&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 21, 2024 in GoodRx Holdings, Inc. Lawsuit – GDRX

NEW YORK, June 19, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of GoodRx Holdings, Inc. (NASDAQ: GDRX) between September 23, 2020 and November 8, 2022, both dates inclusive (the “Class Period”), of the important June 21, 2024 lead plaintiff deadline.

GDRX IMPORTANT DEADLINE FRIDAY: ROSEN, A LEADING AND RANKED FIRM, Encourages GoodRx Holdings, Inc. Investors to Secure Counsel Before Important June 21 Deadline in Securities Class Action – GDRX

NEW YORK, NY / ACCESSWIRE / June 19, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=86337&wire=1 or contact Joseph E. Levi, Esq.

GoodRx Holdings, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - GDRX

LOS ANGELES, CA / ACCESSWIRE / June 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GoodRx Holdings, Inc. ("GoodRx" or "the Company") (NASDAQ:GDRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 23, 2020 and November 8, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before June 21, 2024.

Investors With Losses In GoodRx Holdings Inc Are Encouraged By The Schall Law Firm To Make Contact Prior To The Deadline

BENSALEM, Pa. , June 18, 2024 /PRNewswire/ -- Law Offices of Howard G.

GDRX Investors Have Opportunity to Lead GoodRx Holdings, Inc. Securities Fraud Lawsuit

NEW YORK, NY / ACCESSWIRE / June 18, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=86181&wire=1 or contact Joseph E. Levi, Esq.

Lost Money on GoodRx Holdings, Inc. (GDRX)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / June 18, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=86182&wire=1 or contact Joseph E. Levi, Esq.

Investors in GoodRx Holdings, Inc. Should Contact Levi & Korsinsky Before June 21, 2024 to Discuss Your Rights – GDRX

SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the GoodRx class action lawsuit seeks to represent purchasers or acquirers of GoodRx Holdings, Inc. (NASDAQ: GDRX) common stock between September 23, 2020 and November 8, 2022, inclusive (the “Class Period”) have until this Friday, June 21, 2024 to seek appointment as lead plaintiff of the GoodRx class action lawsuit. Captioned Barsuli v. GoodRx Holdings, Inc., No. 24-cv-03282 (C.D. Cal.), the GoodRx class action lawsuit charges GoodRx and certain of GoodRx's top executives and directors with violations of the Securities Exchange Act of 1934.

INVESTOR DEADLINE FRIDAY: Robbins Geller Rudman & Dowd LLP Announces that GoodRx Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GDRX

NEW YORK, June 18, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of GoodRx Holdings, Inc. (NASDAQ: GDRX).

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 21, 2024 in GoodRx Lawsuit – GDRX

NEW YORK, NY / ACCESSWIRE / June 18, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=86079&wire=1 or contact Joseph E. Levi, Esq.

Investors in GoodRx Holdings, Inc. Should Contact Levi & Korsinsky Before June 21, 2024 to Discuss Your Rights - GDRX

LOS ANGELES, CA / ACCESSWIRE / June 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GoodRx Holdings, Inc. ("GoodRx" or "the Company") (NASDAQ:GDRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 23, 2020 and November 8, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before June 21, 2024.

The Schall Law Firm Encourages Investors Who Have Suffered Losses In GoodRx Holdings Inc To Make Contact Before The Deadline

NEW YORK, NY / ACCESSWIRE / June 18, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=86061&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Notifies GoodRx Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - GDRX

NEW YORK , June 18, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in GoodRx Holdings, Inc. ("GoodRx" or the "Company") (NASDAQ: GDRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of GoodRx investors who were adversely affected by alleged securities fraud between September 23, 2020 and November 8, 2022.

Class Action Filed Against GoodRx Holdings, Inc. (GDRX) Seeking Recovery for Investors - Contact Levi & Korsinsky

NEW YORK, NY / ACCESSWIRE / June 17, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=85964&wire=1 or contact Joseph E. Levi, Esq.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 21, 2024 in GoodRx Lawsuit – GDRX

LOS ANGELES, CA / ACCESSWIRE / June 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against GoodRx Holdings, Inc. ("GoodRx" or "the Company") (NASDAQ:GDRX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between September 23, 2020 and November 8, 2022, inclusive (the "Class Period"), are encouraged to contact the firm before June 21, 2024.

The Schall Law Firm Urges Investors Who Have Incurred Losses With GoodRx Holdings Inc To Reach Out Prior To The Deadline

NEW YORK, NY / ACCESSWIRE / June 17, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=85870&wire=1 or contact Joseph E. Levi, Esq.

GoodRx Holdings, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before June 21, 2024 to Discuss Your Rights - GDRX

NEW YORK, NY / ACCESSWIRE / June 17, 2024 / If you suffered a loss on your GoodRx Holdings, Inc. (NASDAQ:GDRX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/goodrx-lawsuit-submission-form?prid=85874&wire=1 or contact Joseph E. Levi, Esq.

GDRX LAWSUIT ALERT: Levi & Korsinsky Notifies GoodRx Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

RADNOR, Pa. , June 17, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities fraud class action lawsuit against GoodRx Holdings, Inc. (NASDAQ: GDRX) ("GoodRx" or the "Company") on behalf of investors who purchased or acquired GoodRx common stock between September 23, 2020, and November 8, 2022, inclusive (the "Class Period").

Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Class Action Lawsuit Against GoodRx Holdings, Inc. (GDRX)

NEW YORK, NY / ACCESSWIRE / June 17, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against GoodRx Holdings, Inc. ("GoodRx" or the "Company") (NASDAQ:GDRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against GoodRx Holdings, Inc. - GDRX

LOS ANGELES--(BUSINESS WIRE)--GDRX Investors Have Opportunity to Join GoodRx Holdings, Inc. Securities Fraud Investigation with the Schall Law Firm.

GDRX Investors Have Opportunity to Join GoodRx Holdings, Inc. Securities Fraud Investigation with the Schall Law Firm

SAN DIEGO, CA / ACCESSWIRE / June 17, 2024 / Robbins Geller Rudman & Dowd LLP announces that the GoodRx class action lawsuit seeks to represent purchasers or acquirers of GoodRx Holdings, Inc. (NASDAQ:GDRX) common stock between September 23, 2020 and November 8, 2022, inclusive (the "Class Period") have until Friday, June 21, 2024 to seek appointment as lead plaintiff of the GoodRx class action lawsuit. Captioned Barsuli v.

FRIDAY INVESTOR DEADLINE: GoodRx Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GDRX

ChargePoint Holdings

JinkoSolar Holding

As the June 27th presidential debate approaches, the associated volatility is expected to shake the markets, potentially positioning some stocks as riskier bets. Historically, political events like debates can introduce uncertainty that affects stock prices, making it crucial to identify potential stocks to sell to mitigate risks.

News for GoodRx Holdings Stock (GDRX)